MEDLINE INC-CL A (MDLN) Forecast, Price Target & Analyst Ratings

NASDAQ:MDLN • US58507V1070

Current stock price

45.6 USD
-0.09 (-0.2%)
At close:
45.5 USD
-0.1 (-0.22%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEDLINE INC-CL A (MDLN).

Forecast Snapshot

Consensus Price Target

Price Target
$54.65
+ 19.86% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
$0.30
Revenue Estimate
7.306B
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
83.64%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$54.65
Upside
+ 19.86%
From current price of $45.60 to mean target of $54.65, Based on 33 analyst forecasts
Low
$42.42
Median
$56.10
High
$63.00

Price Target Revisions

1 Month
13.24%
3 Months
N/A

Price Target Summary

33 Wall Street analysts provided a forecast for the next 12 months for MDLN. The average price target is 54.66 USD. This implies a price increase of 19.86% is expected in the next year compared to the current price of 45.6.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

MDLN Current Analyst RatingMDLN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10

Analyst Ratings History

MDLN Historical Analyst RatingsMDLN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -2 -1 0 10 20 30

Analyst Ratings Consensus

ChartMill Buy Consensus
83.64%
MDLN was analyzed by 33 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about MDLN.
In the previous month the buy percentage consensus was at a similar level.
MDLN was analyzed by 33 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11CitigroupReiterate Buy
2026-03-10JP MorganMaintains Overweight -> Overweight
2026-03-09Tigress FinancialMaintains Buy -> Buy
2026-03-09BTIGReiterate Buy -> Buy
2026-03-02Morgan StanleyMaintains Overweight -> Overweight
2026-02-27Wells FargoMaintains Equal-Weight -> Equal-Weight
2026-02-26BMO CapitalMaintains Outperform -> Outperform
2026-02-26UBSMaintains Buy -> Buy
2026-02-26RBC CapitalMaintains Outperform -> Outperform
2026-02-26Evercore ISI GroupMaintains Outperform -> Outperform
2026-02-26CitigroupMaintains Buy -> Buy
2026-02-05Tigress FinancialInitiate Buy
2026-01-12Rothschild & CoInitiate Neutral
2026-01-12Leerink PartnersInitiate Outperform
2026-01-12TD CowenInitiate Buy
2026-01-12BernsteinInitiate Outperform
2026-01-12MizuhoInitiate Outperform
2026-01-12BMO CapitalInitiate Outperform
2026-01-12Wolfe ResearchInitiate Outperform
2026-01-12BTIGInitiate Buy
2026-01-12UBSInitiate Buy
2026-01-12Deutsche BankInitiate Hold
2026-01-12RBC CapitalInitiate Outperform
2026-01-12StifelInitiate Buy
2026-01-12BarclaysInitiate Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q1 / 2026
EPS Estimate
$0.30
Revenue Estimate
7.306B
Revenue Q2Q
9.96%
EPS Q2Q
N/A
Number of Analysts
27

Next Earnings Revisions

Revenue (1 Month)
0.66%
Revenue (3 Months)
N/A
EPS (1 Month)
1.59%
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2028

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
MDLN revenue by date.MDLN revenue by date.
23.231B
8.31%		25.507B
9.80%		28.432B
11.47%		31.525B
10.88%		33.949B
7.69%		36.562B
7.70%
EBITDA
YoY % growth
MDLN ebitda by date.MDLN ebitda by date.
2.309B3.268B
41.53%		3.336B
2.08%		3.646B
9.29%		3.985B
9.30%		4.326B
8.56%
EBIT
YoY % growth
MDLN ebit by date.MDLN ebit by date.
1.358B
57.72%		2.291B
68.70%		2.325B
1.48%		3.068B
31.96%		3.423B
11.57%		3.799B
10.98%
Operating Margin
MDLN operating margin by date.MDLN operating margin by date.
5.85%8.98%8.18%9.73%10.08%10.39%
EPS
YoY % growth
MDLN eps by date.MDLN eps by date.
N/AN/AN/A1.49
20.98%		1.68
12.32%		1.90
13.22%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		0.300.340.380.48
4,719.50%		0.36
18.91%		0.40
18.35%		0.42
11.83%		0.52
7.15%		0.41
14.86%		0.47
16.41%		0.46
9.75%		0.57
11.27%
Revenue
Q2Q % growth		7.306B
9.96%		7.639B
10.94%		7.881B
10.77%		8.702B
11.75%		7.751B
6.09%		8.218B
7.58%		8.471B
7.49%		9.427B
8.33%		8.413B
8.54%		8.802B
7.11%		9.055B
6.89%		10.046B
6.57%
EBITDA
Q2Q % growth		798.16M850.35M
-25.34%		910.06M
-31.26%		1.069B
-25.66%		881.11M
10.39%		946.69M
11.33%		983.73M
8.10%		1.134B
6.08%		949.47M
7.76%		1.038B
9.65%		985.03M
0.13%		1.168B
3.00%
EBIT
Q2Q % growth		675.14M
18.24%		732.04M
14.02%		787.16M
37.14%		943.58M
120.98%		773.48M
14.57%		843.16M
15.18%		870.87M
10.63%		1.023B
8.42%		905M
17.00%		993.81M
17.87%		940.56M
8.00%		1.123B
9.78%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

MDLN Yearly Revenue VS EstimatesMDLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 10B 20B 30B
MDLN Yearly EPS VS EstimatesMDLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 0.5 1 1.5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
15.44%
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
8.38%
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
13.23%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MEDLINE INC-CL A / MDLN Forecast FAQ

Can you provide the average price target for MEDLINE INC-CL A stock?

33 analysts have analysed MDLN and the average price target is 54.66 USD. This implies a price increase of 19.86% is expected in the next year compared to the current price of 45.6.

What are the consensus estimates for MDLN stock next earnings?

The consensus EPS estimate for the next earnings of MEDLINE INC-CL A (MDLN) is 0.3 USD and the consensus revenue estimate is 7.31B USD.

What is the consensus rating for MEDLINE INC-CL A (MDLN) stock?

The consensus rating for MEDLINE INC-CL A (MDLN) is 83.6364 / 100 . This indicates that analysts generally have a positive outlook on the stock.